Research Progress on the Mechanism of Ginsenosides in the Treatment of Parkinson’s Disease
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27104544 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Shanshan Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun 130117, China. Hauptthemen laut MEDLINE: Ginsenosides, Parkinson Disease, Neuroprotective Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Natural Science Foundation of Jilin Province, Natural Science Foundation of Jilin Province.
Abstract (Originalsprache)
Parkinson’s disease (PD) is a neurodegenerative disorder of the central nervous system with a complex pathogenesis. Current conventional medicines are predominantly symptomatic treatments, which fail to reverse neuronal degeneration and often induce severe motor complications following long-term administration. In this context, the advantages of the multi-target holistic regulation provided by traditional Chinese medicine have become increasingly prominent. As the core active ingredients of Panax ginseng, ginsenosides can penetrate the blood–brain barrier and exhibit broad neuroprotective prospects in PD treatment. This article systematically reviews the neuroprotective mechanisms of different configurations of ginsenosides—mainly including protopanaxadiol (PPD) and protopanaxatriol (PPT) saponins—against PD. Studies indicate that PPD-type saponins (e.g., Rb1, Rg3, Rd) excel in directly inhibiting the abnormal aggregation of α-synuclein (α-syn), reducing oxidative stress, and preventing neuronal apoptosis. Conversely, PPT-type saponins (e.g., Rg1, Re) demonstrate significant advantages in suppressing microglia-mediated neuroinflammation, improving mitophagy, and regulating lipid metabolism networks. Furthermore, this review highlights a novel intervention strategy utilizing ginsenosides based on antioxidation and iron metabolism regulation. By maintaining the homeostasis of iron transport proteins such as DMT1 (Divalent Metal Transporter 1) and FPN1 (Ferroportin 1), and activating the Nrf2/xCT/GPX4 signaling axis, these compounds effectively block the vicious cycle of “iron deposition-oxidative stress-lipid peroxidation (LPO),” thereby inhibiting ferroptosis in dopaminergic neurons. In summary, structurally diverse ginsenosides exhibit distinct characteristics in targeting the core pathological events of PD. The scientific combination of ginsenoside monomers with different mechanisms in the future holds promise for constructing a comprehensive multi-target neuroprotective network, providing a solid theoretical foundation for novel ginsenoside-based combination therapies against PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun 130117, China.
Förderung
- the Natural Science Foundation of Jilin Province
- Natural Science Foundation of Jilin Province
Zitieren
APA
Wang, S., Chen, Z., Tang, H., Gong, J., Xu, K., & Wang, K. (2026). Research Progress on the Mechanism of Ginsenosides in the Treatment of Parkinson’s Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27104544
Vancouver
Wang S, Chen Z, Tang H, Gong J, Xu K, Wang K. Research Progress on the Mechanism of Ginsenosides in the Treatment of Parkinson’s Disease. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27104544
BibTeX
@article{Wang2026,
author = {Wang, Shanshan and Chen, Zhi and Tang, Haipeng and Gong, Jiyu and Xu, Kejin and Wang, Kangyu},
title = {Research Progress on the Mechanism of Ginsenosides in the Treatment of Parkinson’s Disease},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27104544}
}
EUVIMED